This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Neuroendocrine Tumors

Neuroendocrine tumors are derived from cells that release a hormone in response to a signal from the nervous system. Some examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid carcinoma, and pheochromocytoma. These tumors secrete hormones in excess, causing a variety of symptoms. [Source: www.cancer.gov]

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

The purpose of this clinical research study is to determine if an investigational drug is safe and effective in people who have advanced pancreatic neuroendocrine tumors. This cancer is also known as islet cell carcinoma. The purpose of this clinical research study is to learn if the investigational drug can shrink or slow the growth of the tumors. In order to determine the safety and effectiveness of the investigational drug, the study doctor will monitor the physical state and well being of participants, evaluate changes in the size of their tumors, and perform laboratory tests. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Participants will be asked to take 2 tablets (5 mg each) orally, once a day for a set number of days
Protocol Number: CRAD001C2324

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Neuroendocrine Tumors